Bosh sahifaANTH • OTCMKTS
add
Anthera Pharmaceuticals Inc
Yopilish kursi
0,00 $
Bozor kapitalizatsiyasi
30,00 USD
Oʻrtacha hajm
3,80 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
OTCMKTS
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | 2017info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 7,94 mln | -28,30% |
Sof foyda | -26,87 mln | 51,60% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -3,80 | 70,53% |
EBITDA | -36,15 mln | 36,48% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | 2017info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 2,20 mln | -89,46% |
Jami aktivlari | 3,67 mln | -84,35% |
Jami passivlari | 9,17 mln | -13,70% |
Umumiy kapital | -5,50 mln | — |
Tarqatilgan aksiyalar | 23,40 mln | — |
Narxi/balansdagi bahosi | -0,00 | — |
Aktivlardan daromad | -167,77% | — |
Kapitaldan daromad | -619,42% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | 2017info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -26,87 mln | 51,60% |
Operatsiyalardan naqd pul | -36,90 mln | 24,57% |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | 18,25 mln | -22,58% |
Naqd pulning sof oʻzgarishi | -18,65 mln | 28,58% |
Boʻsh pul | -23,15 mln | 18,17% |
Haqida
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
Tashkil etilgan
2004
Sayt
Xodimlar soni
21
